JO
CSTL icon

John Overdeck’s Castle Biosciences CSTL Stock Holding History

John Overdeck’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Sell
100,374
-148,466
-60% -$3.31M ﹤0.01% 2831
2026
Q1 		$6.11M Buy
248,840
+164,774
+196% +$5.4M ﹤0.01% 1803
2025
Q4 		$3.27M Buy
84,066
+58,366
+227% +$1.88M ﹤0.01% 2079
2025
Q3 		$585K Sell
25,700
-2,541
-9% -$51.6K ﹤0.01% 2911
2025
Q2 		$577K Sell
28,241
-111,544
-80% -$2.07M ﹤0.01% 2522
2025
Q1 		$2.8M Buy
+139,785
New +$3.46M 0.01% 1519
2024
Q4 		– Sell
-9,800
Closed -$279K – 3253
2024
Q3 		$279K Sell
9,800
-7,000
-42% -$178K ﹤0.01% 2698
2024
Q2 		$366K Buy
16,800
+100
+0.6% +$2.23K ﹤0.01% 2513
2024
Q1 		$370K Sell
16,700
-600
-3% -$13.1K ﹤0.01% 2465
2023
Q4 		$373K Buy
17,300
+4,500
+35% +$79.2K ﹤0.01% 2600
2023
Q3 		$216K Sell
12,800
-19,100
-60% -$334K ﹤0.01% 2612
2023
Q2 		$438K Buy
31,900
+9,276
+41% +$188K ﹤0.01% 2384
2023
Q1 		$514K Sell
22,624
-31,321
-58% -$765K ﹤0.01% 2188
2022
Q4 		$1.27M Sell
53,945
-67,603
-56% -$1.57M ﹤0.01% 1575
2022
Q3 		$3.17M Sell
121,548
-27,881
-19% -$782K 0.01% 953
2022
Q2 		$3.28M Buy
+149,429
New +$3.47M 0.01% 946
2022
Q1 		– Sell
-135,367
Closed -$5.8M – 3009
2021
Q4 		$5.8M Buy
135,367
+62,401
+86% +$3.26M 0.01% 1107
2021
Q3 		$4.85M Buy
72,966
+30,028
+70% +$2.11M 0.01% 1251
2021
Q2 		$3.15M Sell
42,938
-49,286
-53% -$3.26M 0.01% 1511
2021
Q1 		$6.31M Buy
92,224
+22,409
+32% +$1.68M 0.02% 923
2020
Q4 		$4.69M Buy
69,815
+65,615
+1,562% +$3.56M 0.01% 977
2020
Q3 		$216K Sell
4,200
-25,852
-86% -$1.15M ﹤0.01% 2778
2020
Q2 		$1.13M Buy
+30,052
New +$1.03M 0.01% 1465

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's CSTL Position: Q2 2026 in Review

John Overdeck reduced its Castle Biosciences (CSTL) stake by 60% in Q2 2026, selling an estimated $3.31M and leaving 100,374 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2831.

John Overdeck first reported a position in CSTL in Q2 2020 and has held it in 23 quarters since. The position peaked at $6.31M in Q1 2021. 175 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • John Overdeck held 100,374 shares of Castle Biosciences worth $2.39M as of Q2 2026.
  • John Overdeck sold 148,466 Castle Biosciences shares in Q2 2026, an estimated $3.31M.
  • Castle Biosciences made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2831 holding.
  • John Overdeck first reported a position in Castle Biosciences in Q2 2020 and has held it in 23 quarters since.
  • John Overdeck's Castle Biosciences position peaked at $6.31M in Q1 2021.
  • 175 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.